Pompe disease is a rare genetic disorder that can be inherited from both parents. It affects people all around the world, no matter what age or gender. For many years, scientists and clinicians believed that 1 in 40,000 people were living with Pompe disease. However, as diagnoses increase and newborn screening becomes more common, this estimate is likely to change.
Twenty years ago, there were few treatment options for people who developed Pompe disease symptoms. Today, there’s a much greater understanding of how Pompe disease can affect people over time and how it can be managed.
When we share knowledge that helps empower decision making—we Pompe Together.
In Pompe disease, the body is missing or has low levels of an enzyme called “acid alpha-glucosidase” (or GAA). GAA works in tiny cellular compartments called “lysosomes” to break down a complex sugar called “glycogen” into a simple sugar called “glucose.” The body uses glucose for energy.
Pompe disease is a multisystem disorder that has varying rates of progression, age of onset, organ involvement, symptoms, and overall severity.
Common symptoms include muscle weakness that affects movement and breathing difficulties that may worsen over time. Other parts of the body can be affected as well.
Depending on the type of GAA gene someone inherits, Pompe disease can affect the body in different ways—influencing how much functioning GAA a person has, when symptoms become noticeable, and how quickly they progress.
Pompe disease can be detected at birth in states where newborn screenings test for the disease. It can also be diagnosed when infants younger than 12 months develop symptoms; this type of Pompe disease is called infantile-onset Pompe disease (IOPD).
In IOPD, babies may have less than 1% of functioning GAA in cells, resulting in symptoms that may appear within one to three months of life and become serious quickly. These babies need treatment right away in order to survive.
Symptoms may vary but can include:
When symptoms develop after one year, it’s often called late-onset Pompe disease (LOPD). LOPD, or delayed-onset Pompe disease, refers to people who are diagnosed at any age from early childhood throughout adulthood. In LOPD, someone may have anywhere from about 1% to 30% of functioning GAA in their cells.
Lower levels of functioning GAA can cause symptoms that appear earlier in life and progress faster than in people with higher levels of GAA.
Testing is available, but getting diagnosed can take time. The earlier someone is diagnosed with Pompe disease, the sooner they can get the right treatment. Newborns with IOPD are often diagnosed within the first few months of life based on signs, symptoms, and the results of laboratory testing. Pompe disease diagnosis can take much longer for older children and adults.
Some states and countries offer screening for Pompe disease at birth. In other cases, getting a correct diagnosis can take years—and many doctor visits—for children and adults with LOPD. There are two big reasons for this delay:
Going to a treatment center that specializes in rare diseases may help someone with puzzling symptoms get a diagnosis sooner.
Once a doctor thinks someone might have Pompe disease, the tests to diagnose it are fairly straightforward.
A chest x-ray and electrocardiogram (ECG) may be used to look for signs of heart disease in possible cases of infantile-onset Pompe disease.
Understand how a genetic counselor could help with the diagnosis journey.
Because of the many challenges that go along with Pompe disease, it often helps to have a team of doctors, therapists, and counselors to support patients and their caregivers.
Today, the main treatment for Pompe disease is enzyme replacement therapy (ERT). By replacing the missing GAA enzyme, ERT can help to stop the buildup of glycogen and slow down progressive muscle weakness. ERT is given to patients through an intravenous (into the vein) infusion every other week.
There is evidence that ERT has helped children with infantile-onset Pompe disease live longer. Most people with the late-onset form experience slowed progression while using ERT, although the benefits of treatment may decrease over time.
One challenge with ERT is that it can’t always reach all the places in the body that need help. Another issue is that some people may develop an immune system reaction that fights the treatment, making it less effective.
Even with ERT, some people may continue to have symptoms and may experience disease progression over time.
A range of supportive care options can help address individual needs and improve quality of life.